NASDAQ:LUMO
Delisted

Lumos Pharma Stock Predictions

etoro logo Buy LUMO
*Your capital is at risk
$4.34
+0 (+0%)
At Close: Mar 10, 2025
Currently predicting for Thu, 6 Aug 2026
LUMO Live board
Community Bull/Bear
Target Next close

Join the LUMO prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

LUMO Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Forecast Desk

3-Month Forecasts For LUMO

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

LUMO Predictions History

Predictor Target Session Target Price Accuracy
Community predictor Next session USD target Record locked
Ranked predictor Previous session Bullish/Bearish Score locked

See the prediction record

Register to view community history, predictor profiles, accuracy, scores, and your own prediction trail for LUMO.

Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Log in or create a free account to view and request 66-session forecasts for LUMO.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT LUMOS PHARMA INC.
Lumos Pharma
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas....
GOLDEN STAR
Ticker Change Signal Date
FCX
$62.63
7.46% Jul 31
MC
$67.08
2.40% Jul 31
ARW
$212.85
6.96% Jul 30
BIIB
$202.19
3.10% Jul 24
F
FERG
$230.67
10.77% Jul 24

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE